Allergan (AGN) Receiving Favorable Media Coverage, Study Finds
Headlines about Allergan (NYSE:AGN) have been trending positive this week, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a coverage optimism score of 2.17 on their scale. InfoTrie also gave news stories about the company an news buzz score of 8 out of 10, meaning that recent news coverage is very likely to have an effect on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Allergan’s analysis:
- Allergan plc (AGN) CEO Brenton Saunders Presents at Citi Global Healthcare Conference (Transcript) (seekingalpha.com)
- Is Allergan plc (AGN) A Good Stock To Buy? (feedproxy.google.com)
- Positive Media Coverage Very Likely to Affect Allergan (AGN) Stock Price (americanbankingnews.com)
- Analysts Weigh in on Allergan Plc (AGN)Apps for PC Daily – AppsforPCdaily (appsforpcdaily.com)
- Global Cognitive and Memory Enhancer Drugs Market 2019- Allergan Plc., AlternaScript LLC, Ceretropic, Eisai Co, Johnson & Johnson – Journal of Industry (industryjournal24.com)
AGN has been the subject of several analyst reports. Cowen set a $255.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Wednesday, October 17th. Guggenheim initiated coverage on shares of Allergan in a report on Monday, October 8th. They issued a “buy” rating for the company. Raymond James restated a “buy” rating and issued a $232.00 price target (up from $211.00) on shares of Allergan in a research note on Monday, September 17th. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research note on Saturday, September 15th. Finally, SunTrust Banks upped their price target on Allergan to $218.00 and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $211.52.
Allergan (NYSE:AGN) last posted its earnings results on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.21. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $4.15 EPS. On average, sell-side analysts expect that Allergan will post 16.52 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a yield of 1.89%. Allergan’s dividend payout ratio is presently 17.61%.
In related news, CFO Matthew M. Walsh purchased 1,000 shares of the stock in a transaction that occurred on Friday, November 16th. The stock was bought at an average cost of $157.00 per share, for a total transaction of $157,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is owned by company insiders.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Recommended Story: Balanced Fund
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.